SYSTEMS, DEVICES, AND METHODS FOR MAKING OR ADMINISTERING FROZEN PARTICLES

• US 20140200511A1
• Filed: 02/28/2014
• Published: 07/17/2014
• Est. Priority Date: 10/30/2009
• Status: Abandoned Application

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Boyden, Edward S., Cook, Daniel B., Hyde, Roderick A., Leuthardt, Eric C., Myhrvold, Nathan P., Sweeney, Elizabeth A., Wood, Lowell L. Jr.
• Application Number:
  US14/193,019
• Publication Number:
  US 20140200511A1
• Time in Patent Office: Days
• US Class Current: 604/67
• CPC Class Codes: A61B 17/00491 Surgical glue applicators surgical adhesives A61L24/00; two-component delivery syringes A61M5/19
• CPC Class Codes: A61B 17/3205 Excision instruments
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 38/38 Albumins
• CPC Class Codes: A61K 38/4833 Thrombin (3.4.21.5)
• CPC Class Codes: A61K 38/4886 Metalloendopeptidases (3.4.24), e.g. collagenase
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/46 Cellular immunotherapy
• CPC Class Codes: A61K 41/0004 Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 51/1244 microparticles or nanoparticles, e.g. polymeric nanoparticles
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/007 Pulmonary tract; Aromatherapy
• CPC Class Codes: A61K 9/08 : Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/1611 : Inorganic compounds
• CPC Class Codes: A61K 9/1617 : Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1641 : obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1664 : Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/1617
• CPC Class Codes: A61K 9/1688 : resulting in pure drug agglomerate optionally containing up to 5% of excipient
• CPC Class Codes: A61K 9/19 : lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61M 37/00 : Other apparatus for introducing media into the body for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30; Percutany, i.e. introducing medicines into the body by diffusion through the skin salt baths A61H33/04
• CPC Class Codes: C07K 16/22 : against growth factors ; against growth regulators
• CPC Class Codes: C07K 16/2863 : against receptors for growth factors, growth regulators

Abstract

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one substrate.

Claims

1. A device, comprising:

at least one propulsion means configured for propelling at least one therapeutic composition to a biological tissue;

at least one delivery means operably linked to the at least one propulsion means and configured for administration of the at least one therapeutic composition to a biological tissue;

at least one ultrasonic image detector;

at least one microprocessor in electronic communication with at least one of the at least one propulsion means, the at least one delivery means, or the at least one ultrasonic image detector, and configured to provide real-time feedback of at least one characteristic of the delivery of the at least one therapeutic composition to the biological tissue.

2. The device of claim 1, wherein the device provides output related to the feedback.

3. The device of claim 1, wherein the at least one microprocessor is further configured to instruct alteration of the delivery of the at least one therapeutic composition based on the real-time feedback.

4. The device of claim 3, wherein the real-time feedback of delivery of at least one therapeutic composition is utilized to alter the delivery of at least one subsequent therapeutic composition.

5. The device of claim 1, wherein the propulsion means includes at least one mechanical or electrical propulsion means.

6. The device of claim 1, wherein the propulsion means includes at least one of an inkjet ejector, fluid ejector, striker, or thermal bubble propulsion.

7. The device of claim 1, wherein the biological tissue includes at least one of skin tissue, muscle tissue, eye tissue, nervous tissue, peritoneal tissue, an organ, connective tissue, neoplastic tissue, or bone tissue.

8. The device of claim 6, wherein the eye tissue includes at least one of retinal tissue, vitreal tissue, ductal tissue, scleral tissue, corneal tissue, lens tissue, lacrimal tissue, musculature of the eye, ligamental tissue of the eye, or neural tissue of the eye.

9. The device of claim 1, wherein the biological tissue includes tumor tissue.

10. The device of claim 1, wherein the propulsion means is configured to deliver the at least one therapeutic composition to or at a velocity of approximately 1 m/s, approximately 5 m/s, approximately 10 m/s, approximately 20 m/s, approximately 30 m/s, approximately 40 m/s, approximately 50 m/s, approximately 60 m/s, approximately 70 m/s, approximately 80 m/s, approximately 90 m/s, approximately 100 m/s, approximately 200 m/s, approximately 300 m/s, approximately 400 m/s, approximately 500 m/s, approximately 600 m/s, approximately 700 m/s, approximately 800 m/s, approximately 900 m/s, approximately 1000 m/s, approximately 1500 m/s, approximately 2000 m/s, approximately 3000 m/s, approximately 4000 m/s, approximately 5000 m/s, or any value greater or therebetween.

11. The device of claim 1, wherein the at least one therapeutic composition includes at least one sugar glass.

12. The device of claim 10, wherein the at least one sugar glass includes one or more of trehalose, glucose, maltose, lactose, multulose, iso-maltulose, lactulose, mono-reducing glycosides of polydydroxy compounds.

13. The device of claim 1, wherein the at least one therapeutic composition includes at least one polyol.

14. The device of claim 1, wherein the at least one frozen particle composition or frozen piercing implement composition further includes at least one sugar glass.

15. The device of claim 13, wherein the at least one sugar glass includes one or more of trehalose, glucose, maltose, lactose, multulose, iso-maltulose, lactulose, mono-reducing glycosides of polydydroxy compounds.

16. The device of claim 1, wherein the at least one frozen particle composition or frozen piercing implement composition includes at least one polyol.

17. The device of claim 1, wherein the at least one therapeutic composition includes at least one frozen particle composition or frozen piercing implement composition.

18. The device of claim 16, wherein the at least one frozen particle composition or frozen piercing implement composition further includes at least one sugar glass.

19. The device of claim 17, wherein the at least one sugar glass includes one or more of trehalose, glucose, maltose, lactose, multulose, iso-maltulose, lactulose, mono-reducing glycosides of polydydroxy compounds.

20. The device of claim 16, wherein the at least one frozen particle composition or frozen piercing implement composition includes at least one polyol.

21. The device of claim 1, wherein the feedback of the at least one characteristic of the delivery includes one or more of the amount of the at least one therapeutic composition delivered, the content of the at least one therapeutic composition delivered, the depth of penetration of the at least one therapeutic composition, the trajectory of the at least one therapeutic composition, the configuration of the at least one therapeutic composition, status of the at least one therapeutic composition, status of the target biological tissue, determination of first delivery of the at least one therapeutic composition, status of a spatial or temporal delivery pattern, specific spatial or temporal location of the at least one therapeutic composition delivered, velocity of delivery of the at least one therapeutic composition, deceleration of the at least one therapeutic composition upon delivery, or status of the delivery device itself.

22. The device of claim 1, further including at least one magnetic deflector configured to assist in directing the at least one therapeutic composition.

23. The device of claim 1, wherein the at least one therapeutic composition is biodegradable.

24. The device of claim 1, wherein the at least one frozen particle composition or frozen piercing implement composition includes at least one of a therapeutic agent, reinforcement agent, biological remodeling agent, adhesive agent, or abrasive.

25. The device of claim 1, wherein the therapeutic agent includes at least one of an anti-inflammatory agent, coagulant, anti-microbial agent, anesthetic, analgesic;

vasodilator, immunological agent, angiogenic factor, anti-angiogenic factor, vasoconstrictor, or growth factor inhibitor.

26. A system, comprising:

a device including at least one propulsion means configured for propelling at least one therapeutic composition to a biological tissue;

at least one delivery means operably linked to the at least one propulsion means and configured for administration of the at least one therapeutic composition to a biological tissue;

at least one ultrasonic image detector;

at least one microprocessor in electronic communication with at least one of the at least one propulsion means, the at least one delivery means, or the at least one ultrasonic image detector, and configured to provide real-time feedback of at least one characteristic of the delivery of the at least one therapeutic composition to the biological tissue.

27. The system of claim 26, wherein the at least one microprocessor is further configured to instruct alteration of the delivery of the at least one therapeutic composition based on the real-time feedback.

28. The system of claim 27, wherein the real-time feedback of delivery of at least one therapeutic composition is utilized to alter the delivery of at least one subsequent therapeutic composition.

29. The system of claim 26, wherein the propulsion means includes at least one mechanical or electrical propulsion means.

30. The system of claim 26, wherein the propulsion means includes at least one of an inkjet ejector, fluid ejector, striker, or thermal bubble propulsion.

31. The system of claim 26, wherein the biological tissue includes at least one of skin tissue, muscle tissue, eye tissue, nervous tissue, peritoneal tissue, an organ, connective tissue, neoplastic tissue, or bone tissue.

32. The system of claim 31, wherein the eye tissue includes at least one of retinal tissue, vitreal tissue, ductal tissue, scleral tissue, corneal tissue, lens tissue, lacrimal tissue, musculature of the eye, ligamental tissue of the eye, or neural tissue of the eye.

33. The system of claim 26, wherein the biological tissue includes tumor tissue.

34. The system of claim 26, wherein the propulsion means is configured to deliver the at least one therapeutic composition to or at a velocity of approximately 1 m/s, approximately 5 m/s, approximately 10 m/s, approximately 20 m/s, approximately 30 m/s, approximately 40 m/s, approximately 50 m/s, approximately 60 m/s, approximately 70 m/s, approximately 80 m/s, approximately 90 m/s, approximately 100 m/s, approximately 200 m/s, approximately 300 m/s, approximately 400 m/s, approximately 500 m/s, approximately 600 m/s, approximately 700 m/s, approximately 800 m/s, approximately 900 m/s, approximately 1000 m/s, approximately 1500 m/s, approximately 2000 m/s, approximately 3000 m/s, approximately 4000 m/s, approximately 5000 m/s, or any value greater or therebetween.

35. The system of claim 26, wherein the at least one therapeutic composition includes at least one sugar glass.

36. The system of claim 35, wherein the at least one sugar glass includes one or more of trehalose, glucose, maltose, lactose, multulose, iso-maltulose, lactulose, mono-reducing glycosides of polydydroxy compounds.

37. The system of claim 26, wherein the at least one therapeutic composition includes at least one polyol.

38. The system of claim 26, wherein the at least one frozen particle composition or frozen piercing implement composition further includes at least one sugar glass.

39. The system of claim 38, wherein the at least one sugar glass includes one or more of trehalose, glucose, maltose, lactose, multulose, iso-maltulose, lactulose, mono-reducing glycosides of polydydroxy compounds.

40. The system of claim 26, wherein the at least one frozen particle composition or frozen piercing implement composition includes at least one polyol.

41. The system of claim 26, wherein the at least one therapeutic composition includes at least one frozen particle composition or frozen piercing implement composition.

42. The system of claim 41, wherein the at least one frozen particle composition or frozen piercing implement composition further includes at least one sugar glass.

43. The system of claim 42, wherein the at least one sugar glass includes one or more of trehalose, glucose, maltose, lactose, multulose, iso-maltulose, lactulose, mono-reducing glycosides of polydydroxy compounds.

44. The system of claim 41, wherein the at least one frozen particle composition or frozen piercing implement composition includes at least one polyol.

45. The system of claim 26, wherein the feedback of the at least one characteristic of the delivery includes one or more of the amount of the at least one therapeutic composition delivered, the content of the at least one therapeutic composition delivered, the depth of penetration of the at least one therapeutic composition, the trajectory of the at least one therapeutic composition, the configuration of the at least one therapeutic composition, status of the at least one therapeutic composition, status of the target biological tissue, determination of first delivery of the at least one therapeutic composition, status of a spatial or temporal delivery pattern, specific spatial or temporal location of the at least one therapeutic composition delivered, velocity of delivery of the at least one therapeutic composition, deceleration of the at least one therapeutic composition upon delivery, or status of the delivery device itself.

46. The system of claim 26, further including at least one magnetic deflector configured to assist in directing the at least one therapeutic composition.

47. The system of claim 26, wherein the at least one therapeutic composition is biodegradable.

48. The system of claim 26, wherein the at least one frozen particle composition or frozen piercing implement composition includes at least one of a therapeutic agent, reinforcement agent, biological remodeling agent, adhesive agent, or abrasive.

49. The system of claim 26, wherein the therapeutic agent includes at least one of an anti-inflammatory agent, coagulant, anti-microbial agent, anesthetic, analgesic;

vasodilator, immunological agent, angiogenic factor, anti-angiogenic factor, vasoconstrictor, or growth factor inhibitor.